Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL 200 IN PLASTIC CONTAINER.
DIONOSIL AQUEOUS vs IOPAMIDOL-200 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent